LUCD — Lucid Diagnostics Share News
0.000.00%
Last trade - 00:00- $206.03m
- $213.49m
- $4.71m
Brief: Lucid Diagnostics' Esoguard BE-1 Prospective Multicenter Clinical Validation Study Of Esoguard Esophageal Precancer Testing Accepted For Peer-Reviewed Publication
Tesla surges, other EV makers fall as Trump elected president
Brief: Lucid Diagnostics And Pavmed's Unit Embarked On Expansion Of Direct Contracting Initiative
Brief: Lucid Diagnostics Receives Notice Of Allowance For Key Patent Underlying Its Esoguard Esophageal DNA Test
Brief: Pavmed Announces Efforts To Regain Compliance With Nasdaq Listing Requirements
Brief: Lucid Diagnostics Signs Memorandum Of Understanding With Front Line Mobile Health
Brief: Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard
Lucid Diagnostics Inc reports results for the quarter ended in June - Earnings Summary
Lucid Diagnostics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study
Brief: Lucid Diagnostics Inc Files For Offering Of Up To 72.4 Million Shares By The Selling Stockholders - SEC Filing
Brief: Lucid Diagnostics Inc -Received Notice From Nasdaq, Notified Failure To Satisfy A Continued Listing Rule Or Standard By Co's Common Stock
U.S. RESEARCH ROUNDUP-Chord Energy, PVH, Saia
Brief: Lucid Diagnostics Has Determined To Reschedule 2024 Annual Meeting Of Stockholders
Lucid Diagnostics Inc reports results for the quarter ended in January - Earnings Summary
Lucid Diagnostics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo & Co
Lucid Diagnostics Inc reports results for the quarter ended in December - Earnings Summary